Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.

Kuemmel, Sherko; Tondini, Carlo A; Abraham, Jacinta; Nowecki, Zbigniew; Itrych, Bartosz; Hitre, Erika; Karaszewska, Boguslawa; Juárez-Ramiro, Alejandro; Morales-Vásquez, Flavia; Pérez-García, Jose Manuel; Cardona-Huerta, Servando; Monturus, Estefania; Sequi, Marco; Restuccia, Eleonora; Benyunes, Mark; Martín, Miguel.

Breast Cancer Res Treat ; 187(2): 467-476, 2021 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-33748921

2.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Swain, Sandra M; Miles, David; Kim, Sung-Bae; Im, Young-Hyuck; Im, Seock-Ah; Semiglazov, Vladimir; Ciruelos, Eva; Schneeweiss, Andreas; Loi, Sherene; Monturus, Estefanía; Clark, Emma; Knott, Adam; Restuccia, Eleonora; Benyunes, Mark C; Cortés, Javier.

Lancet Oncol ; 21(4): 519-530, 2020 04.

Artículo en Inglés | MEDLINE | ID: mdl-32171426

3.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz, Gunter; Procter, Marion; de Azambuja, Evandro; Zardavas, Dimitrios; Benyunes, Mark; Viale, Giuseppe; Suter, Thomas; Arahmani, Amal; Rouchet, Nathalie; Clark, Emma; Knott, Adam; Lang, Istvan; Levy, Christelle; Yardley, Denise A; Bines, Jose; Gelber, Richard D; Piccart, Martine; Baselga, Jose.

N Engl J Med ; 377(2): 122-131, 2017 Jul 13.

Artículo en Inglés | MEDLINE | ID: mdl-28581356

4.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Swain, Sandra M; Baselga, José; Kim, Sung-Bae; Ro, Jungsil; Semiglazov, Vladimir; Campone, Mario; Ciruelos, Eva; Ferrero, Jean-Marc; Schneeweiss, Andreas; Heeson, Sarah; Clark, Emma; Ross, Graham; Benyunes, Mark C; Cortés, Javier.

N Engl J Med ; 372(8): 724-34, 2015 Feb 19.

Artículo en Inglés | MEDLINE | ID: mdl-25693012

5.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Baselga, José; Cortés, Javier; Kim, Sung-Bae; Im, Seock-Ah; Hegg, Roberto; Im, Young-Hyuck; Roman, Laslo; Pedrini, José Luiz; Pienkowski, Tadeusz; Knott, Adam; Clark, Emma; Benyunes, Mark C; Ross, Graham; Swain, Sandra M.

N Engl J Med ; 366(2): 109-19, 2012 Jan 12.

Artículo en Inglés | MEDLINE | ID: mdl-22149875

6.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Swain, Sandra M; Kim, Sung-Bae; Cortés, Javier; Ro, Jungsil; Semiglazov, Vladimir; Campone, Mario; Ciruelos, Eva; Ferrero, Jean-Marc; Schneeweiss, Andreas; Knott, Adam; Clark, Emma; Ross, Graham; Benyunes, Mark C; Baselga, José.

Lancet Oncol ; 14(6): 461-71, 2013 May.

Artículo en Inglés | MEDLINE | ID: mdl-23602601

7.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Swain, Sandra M; Ewer, Michael S; Cortés, Javier; Amadori, Dino; Miles, David; Knott, Adam; Clark, Emma; Benyunes, Mark C; Ross, Graham; Baselga, José.

Oncologist ; 18(3): 257-64, 2013.

Artículo en Inglés | MEDLINE | ID: mdl-23475636

8.

Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.

Quartino, Angelica L; Li, Hanbin; Jin, Jin Y; Wada, D Russell; Benyunes, Mark C; McNally, Virginia; Viganò, Lucia; Nijem, Ihsan; Lum, Bert L; Garg, Amit.

Cancer Chemother Pharmacol ; 79(2): 353-361, 2017 02.

Artículo en Inglés | MEDLINE | ID: mdl-28074265

9.

Rituximab: ongoing and future clinical development.

Grillo-López, Antonio J; Hedrick, Eric; Rashford, Michelle; Benyunes, Mark.

Semin Oncol ; 29(1 Suppl 2): 105-12, 2002 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-11842397

10.

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

Czuczman, Myron S; Fallon, Alexandra; Mohr, Alice; Stewart, Carleton; Bernstein, Zale P; McCarthy, Philip; Skipper, Marion; Brown, Karen; Miller, Kena; Wentling, Diane; Klippenstein, Donald; Loud, Peter; Rock, Mike K; Benyunes, Mark; Grillo-López, Antonio J; Bernstein, Steven H.

Semin Oncol ; 29(1 Suppl 2): 36-40, 2002 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-11842387

11.

Rituximab: Ongoing and future clinical development.

Grillo-López, Antonio J; Hedrick, Eric; Rashford, Michelle; Benyunes, Mark.

Semin Oncol ; 29(1S2): 105-112, 2002 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-28140083

12.

Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.

Linker, Charles; Anderlini, Paolo; Herzig, Roger; Christiansen, Neal; Somlo, George; Bensinger, William; Fay, Joseph; Lynch, Joseph P; Goodnough, Lawrence T; Ashby, Mark; Benyunes, Mark C; Jones, Dennie V; Yang, Timothy A; Miller, Langdon L; Weaver, Charles.

Biol Blood Marrow Transplant ; 9(6): 405-13, 2003 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-12813449

13.

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

Czuczman, Myron S; Fallon, Alexandra; Mohr, Alice; Stewart, Carleton; Bernstein, Zale P; McCarthy, Philip; Skipper, Marion; Brown, Karen; Miller, Kena; Wentling, Diane; Klippenstein, Donald; Loud, Peter; Rock, Mike K; Benyunes, Mark; Grillo-López, Antonio J; Bernstein, Steven H.

Semin Oncol ; 29(1S2): 36-40, 2002 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-28140090

14.

Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.

Gajewski, James L; Rondon, Gabriela; Donato, Michele L; Anderlini, Paolo; Korbling, Martin; Ippoliti, Cindy; Benyunes, Mark; Miller, Langdon L; LaTemple, Denise; Jones, Denny; Ashby, Mark; Hellmann, Sue; Durett, April; Lauppe, Jo; Geisler, Deborah; Khouri, Issa F; Giralt, Sergio A; Andersson, Borje; Ueno, Naoto T; Champlin, Richard.

Biol Blood Marrow Transplant ; 8(10): 550-6, 2002.

Artículo en Inglés | MEDLINE | ID: mdl-12434950

15.

No clinical evidence for CD4+ cell depletion caused by rituximab.

Saville, M Wayne; Benyunes, Mark C; Multani, Pratik S.

Blood ; 102(1): 408; author reply 408-9, 2003 Jul 01.

Artículo en Inglés | MEDLINE | ID: mdl-12814917

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.

Rituximab: ongoing and future clinical development.

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

Rituximab: Ongoing and future clinical development.

Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.

No clinical evidence for CD4+ cell depletion caused by rituximab.